Sogroya: payments to doctors
Payments that named Sogroya as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.2M
- Providers
- 1,453
- Transactions
- 5,161
- Average per transaction
- $238
The per-transaction average — $238 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 1,453 providers the average total is $844, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Novo Nordisk | $1,161,676 | 94.7% |
| Novo Nordisk Health Care AG | $55,982 | 4.6% |
| Novo Nordisk AS | $9,200 | 0.7% |